Bioventus (BVS) Shares Outstanding (Weighted Average) (2021 - 2026)

Bioventus (BVS) has 6 years of Shares Outstanding (Weighted Average) data on file, last reported at $67.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 1.95% year-over-year to $67.3 million; the trailing twelve-month figure through Mar 2026 stood at $67.3 million (up 1.95% YoY), and the FY2025 full-year result was $66.6 million, up 3.21% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $67.3 million, up from $66.6 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $67.3 million in Q1 2026 and bottomed at $60.5 million in Q2 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $63.4 million (2024), against an average of $63.7 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) jumped 47.05%; it then increased 1.75% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $61.4 million in 2022, then grew by 2.05% to $62.6 million in 2023, then gained by 3.03% to $64.5 million in 2024, then advanced by 3.21% to $66.6 million in 2025, then climbed by 1.01% to $67.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $67.3 million (Q1 2026), $66.6 million (Q4 2025), and $66.5 million (Q3 2025), per Business Quant data.

Peer Comparison